Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
NEUTRAL SIGNAL
██.█% Sign up free to reveal

Bridgebio Oncology Therapeutics, Inc. (BBOT) AI Forecast

Our AI analyzed Bridgebio Oncology Therapeutics, Inc.. Create a free account and follow it to see the 90-day price prediction.

✓ Free account • ✓ 30-day free trial

$BBOT Neutral Signal Full forecast available
Sign Up Free

Bridgebio Oncology Therapeutics, Inc. (BBOT) Stock Forecast 2025

Bridgebio Oncology Therapeutics, Inc. (BBOT) AI Stock Price Forecast & Investment Analysis

Bridgebio Oncology Therapeutics, Inc. Stock Price Chart and Technical Analysis

Loading chart...

Bridgebio Oncology Therapeutics, Inc. (BBOT) - Comprehensive Stock Analysis & Investment Research

Deep dive into Bridgebio Oncology Therapeutics, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on July 27, 2026, 9:09 p.m. (UTC)

Bridgebio Oncology Therapeutics, Inc. Investment Summary

When evaluating whether Bridgebio Oncology Therapeutics, Inc. (BBOT) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Bridgebio Oncology Therapeutics, Inc. (BBOT) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry. . With a market capitalization of $711 million, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.

Financial Performance Analysis

Our comprehensive financial analysis covers Bridgebio Oncology Therapeutics, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Bridgebio Oncology Therapeutics, Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Bridgebio Oncology Therapeutics, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Bridgebio Oncology Therapeutics, Inc.

Sign Up Free
Corporate Identity

Bridgebio Oncology Therapeutics, Inc. (Stock Symbol: BBOT) is a prominent company operating within the Life Sciences sector, with a specific focus on the Pharmaceutical Preparations industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Bridgebio Oncology Therapeutics, Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Bridgebio Oncology Therapeutics, Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Bridgebio Oncology Therapeutics, Inc....

Unlock Full Company Profile

Get complete details about Bridgebio Oncology Therapeutics, Inc.

Sign Up Free
Revenue & Growth Analysis
Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Bridgebio Oncology Therapeutics, Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Bridgebio Oncology Therapeutics, Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Bridgebio Oncology Therapeutics, Inc....

Unlock Financial Analysis

Get complete financial metrics for Bridgebio Oncology Therapeutics, Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Bridgebio Oncology Therapeutics, Inc.'s AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Bridgebio Oncology Therapeutics, Inc. strategically competes in the highly dynamic Pharmaceutical Preparations marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.

Industry Competitive Landscape

Bridgebio Oncology Therapeutics, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company currently shows negative free cash flow of $-199 million , with year-over-year cash flow growth of -99.5%. Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.

Financial Strength & Leverage

Current ratio of 6.16 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Bridgebio Oncology Therapeutics, Inc. (BBOT) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Bridgebio Oncology Therapeutics, Inc. stock analysis.

Deep dive into Bridgebio Oncology Therapeutics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Bridgebio Oncology Therapeutics, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Bridgebio Oncology Therapeutics, Inc.:

P/B Ratio 1.91x
Market Cap $711M
Book Value/Share $4.65
FCF/Share $-2.49
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Bridgebio Oncology Therapeutics, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Bridgebio Oncology Therapeutics, Inc.:

ROIC -0.2%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Bridgebio Oncology Therapeutics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Bridgebio Oncology Therapeutics, Inc.: A current ratio of 6.16 indicates strong liquidity.

Current Ratio 6.16x
D/E Ratio 0.12x
Financial Leverage 1.12x
Working Capital $223M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Bridgebio Oncology Therapeutics, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Bridgebio Oncology Therapeutics, Inc.: Free cash flow of $-199M indicates cash challenges that need attention.

Operating Cash Flow -$760K
Free Cash Flow -$199M
Capital Spending -$198M
OCF Growth YoY -99.5%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Bridgebio Oncology Therapeutics, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Bridgebio Oncology Therapeutics, Inc.:

Understanding Financial Statement Data

What these metrics mean: Key figures from Bridgebio Oncology Therapeutics, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Bridgebio Oncology Therapeutics, Inc.:

Income Statement
Balance Sheet Highlights (% Of Assets)
Total Current Assets 267%
Cash & Short-term Investments 53%
Total Liabilities 45%
Short-term Debt 31%
Dividend & Shareholder Information
Shares Outstanding 80M

Latest Bridgebio Oncology Therapeutics, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Bridgebio Oncology Therapeutics, Inc. (BBOT) stock price and investment outlook.

📰 Loading...

Bridgebio Oncology Therapeutics, Inc. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Bridgebio Oncology Therapeutics, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
AARD ██% $146M x 1.7x
ABBV ██% $454.62B 125.1x x
ABCL ██% $1.60B x 1.7x
ABEO ██% $349M 5.3x 2.4x
ABT ██% $182.14B 29.0x 3.5x
ABUS ██% $869M 5.4x 3.3x
ABVC ██% $26M x 2.4x
ABVX ██% $10.05B x x
ACAD ██% $4.34B 11.6x 3.5x
ACET ██% $79M x 0.6x
ACRS ██% $750M x 5.2x
ACRV ██% $60M x 0.6x
ACUT ██% $4M x x
ACXP ██% $6M x 0.9x
ADAG ██% $233M x 6.2x
ADCT ██% $145M x x
ADIL ██% $6M x 1.7x
ADTX ██% $3M x x
ADXN ██% $7M x x
AEON ██% $11M x x
AGIO ██% $2.19B x 2.0x
AKBA ██% $343M x 12.5x
AKTX ██% $15M x 1.0x
ALDX ██% $96M x 2.3x
ALKS ██% $8.78B 57.5x 5.0x
ALLR ██% $19M x 2.8x
ALMS ██% $3.39B x 6.0x
ALNY ██% $36.85B 117.5x 46.7x
ALT ██% $576M x 2.0x
ALXO ██% $272M x 1.8x
ALZN ██% $5M x 7.0x
AMLX ██% $2.16B x 7.9x
AMPH ██% $842M 10.6x 1.1x
AMRN ██% $290M x 0.6x
AMRX ██% $5.68B 46.5x x
ANAB ██% $1.56B x 122.1x
ANEB ██% $12M x 1.6x
ANIP ██% $1.64B 17.8x 2.9x
ANIX ██% $116M x 8.0x
ANNX ██% $807M x 4.0x
ANRO ██% $941M x 3.9x
ANTX ██% $177M x 2.2x
ANVS ██% $74M x 23.8x
APLM ██% $41M x x
APRE ██% $8M x 0.2x
APUS ██% $8M x 0.1x
APVO ██% $5M x 0.5x
AQST ██% $468M x x
ARCT ██% $165M x 0.9x
ARDX ██% $1.27B x 8.5x
ARQT ██% $3.42B x 18.0x
ARTL ██% $4M x 0.5x
ARVN ██% $524M x 1.4x
ARWR ██% $12.20B x 19.9x
ASBP ██% $9M x 2.4x
ASMB ██% $500M x 2.5x
ASND ██% $15.66B x x
ASRT ██% $151M x 2.0x
ATAI ██% $2.65B x 16.6x
ATHE ██% $85M x x
ATNM ██% $28M x 12.1x
ATOS ██% $21M x 0.7x
ATXI ██% $910K x 0.8x
AUPH ██% $1.99B 6.7x 3.5x
AVBP ██% $1.43B x 4.4x
AVIR ██% $388M x 1.7x
AVTX ██% $1.05B x 15.4x
AXIM ██% $1M x x
AXSM ██% $12.42B x 227.5x
AZTR ██% $2M x 0.2x
BBIO ██% $16.23B x x
BBOT ██% $711M x 1.9x
BCAX ██% $1.82B x 3.5x
BCTX ██% $32M x 1.3x
BCYC ██% $290M x 0.5x
BDPT ██% $10K x x
BDRX ██% $2M x x
BFRG ██% $11M x 2.3x
BFRI ██% $13M x 2.1x
BHC ██% $1.72B x x
BHST ██% $45M x 1.8x
BIOA ██% $972M x 2.6x
BIOE ██% $13M 9.7x x
BIOM ██% $510K x x
BIVI ██% $11M x 0.7x
BIXT ██% $3M x x
BLRX ██% $13M x x
BLTE ██% $6.10B x 7.9x
BMEA ██% $91M x 4.9x
BMRN ██% $11.38B 42.3x 1.8x
BMY ██% $125.36B 17.2x 6.3x
BNTC ██% $396M x 2.2x
BOLD ██% $56M x 0.7x
BOLT ██% $7M x 0.4x
BPTH ██% $2M x x
BQST ██% $2M x x
BRNS ██% $25M x 0.4x
BSPK ██% $10K x x
BTAI ██% $24M x x
BYSI ██% $44M x x
CALC ██% $11M x x
CANF ██% $7M x 1.2x
CAPR ██% $1.14B x 4.1x
CATX ██% $336M x 1.0x
CBIO ██% $629M x 6.2x
CDT ██% $2M x x
CING ██% $62M x 3.3x
CLCS ██% $65M x x
CLNN ██% $65M x x
CLRB ██% $20M x 5.9x
CLSDQ ██% $1M x x
CLYM ██% $731M x 4.9x
CMMB ██% $10M x 0.8x
CMND ██% $2M x x
CMPS ██% $1.58B x 4.8x
CNBX ██% N/A x x
CNSP ██% $8M x 111.8x
CNTA ██% $6.27B x 12.9x
CNTB ██% $138M x 3.2x
CNTX ██% $54M x 1.0x
COCP ██% $13M x 3.1x
COGT ██% $6.87B x 11.3x
COLL ██% $1.15B 15.4x 3.7x
CORT ██% $10.09B 213.2x 15.8x
COYA ██% $103M x 2.1x
CPHI ██% $75M x 2.0x
CPIX ██% $102M x 4.7x
CPMD ██% $1M x x
CPRX ██% $3.85B 17.4x 3.8x
CRBP ██% $165M x 1.3x
CRMD ██% $631M 3.5x 1.4x
CRNX ██% $8.81B x 6.9x
CRVO ██% $25M x 2.3x
CRVS ██% $1.15B x 4.8x
CTMX ██% $725M x 2.3x
CTNM ██% $537M x 2.2x
CTOR ██% $54M x 1.5x
CTTH ██% $4M x 5.3x
CTXR ██% $14M x 0.2x
CUE ██% $136M x 6.3x
CURX ██% $6M x 0.7x
CVKD ██% $6M x 3.5x
CVSI ██% $4M x 2.6x
CYCN ██% $15M x 2.3x
CYDY ██% $285M x x
CYPH ██% $62M x 0.7x
CYRX ██% $759M 9.5x 1.5x
CYTK ██% $11.12B x x
DARE ██% $18M x 25.0x
DCOY ██% $3M x 0.7x
DERM ██% $180M x 5.8x
DMAC ██% $367M x 7.8x
DMRA ██% $1.83B x 3.6x
DNTH ██% $5.72B x 4.8x
DRMA ██% $5M x 0.8x
DRUG ██% $700M x x
DSGN ██% $726M x 3.3x
DWTX ██% $51M x 0.6x
DYN ██% $3.95B x 4.6x
EBS ██% $388M x 0.7x
EDSA ██% $50M x 4.9x
ELAB ██% $4M x 0.3x
ELAN ██% $12.37B x 1.9x
ELDN ██% $284M x 6.3x
ELTP ██% $409M 9.1x 4.1x
ELTX ██% $83M x x
ELVN ██% $3.77B x 8.3x
EMMA ██% $820K x x
ENLV ██% $73M 0.0x 0.0x
ENSC ██% $4M x x
ENTA ██% $376M x 3.2x
ENVB ██% $5M x 1.1x
EOLS ██% $404M x x
EPRX ██% $412M x 5.0x
EQ ██% $161M x 2.7x
ERAS ██% $6.01B x 15.3x
ERNA ██% $5M x 0.7x
ESPR ██% $799M x x
ETON ██% $1.21B x 39.5x
ETST ██% $35M 7.2x 5.0x
EVFM ██% $1M x x
EVMN ██% $408M x 1.3x
EWTX ██% $4.45B x 9.0x
FBIO ██% $114M 0.9x 0.7x
FBLG ██% $4M x 1.5x
FBRX ██% $1.57B x 37.2x
FHTX ██% $298M x x
FLNA ██% $45M x 0.7x
FTH ██% $716M x x
FULC ██% $250M x 0.8x
GALT ██% $227M x x
GANX ██% $77M x 5.5x
GCAN ██% $260K x x
GDTC ██% $10M x x
GERN ██% $963M x 4.2x
GHRS ██% $1.73B x x
GLMD ██% $3M x 0.2x
GLSI ██% $193M x 36.7x
GNLX ██% $133M x 5.8x
GNPX ██% $4M x 0.2x
GOSS ██% $70M x x
GOVX ██% $4M x 8.9x
GPCR ██% $3.61B x 2.5x
GRCE ██% $39M x 0.6x
GRI ██% $3M x 0.3x
GRTX ██% $3.38B 22.7x 4646.0x
GSK ██% $101.62B x x
GTBP ██% $12M x 1.6x
GYRE ██% $670M x 6.6x
HCM ██% $1.88B 2.1x 1.5x
HCWB ██% $4M x 0.7x
HELP ██% $479M x x
HEPA ██% $1M x 0.7x
HIND ██% $15M x 2.2x
HOOK ██% $14M x 0.4x
HOWL ██% $17M x 1.4x
HRMY ██% $2.07B 14.2x 2.3x
HRTX ██% $87M x 9.6x
HSTC ██% $99M x 79.9x
HURA ██% $137M x 5.9x
HYFT ██% $55M x x
HYPD ██% $40M x 0.7x
IBIO ██% $70M x 0.9x
IBO ██% $46M x 4.0x
IDYA ██% $3.22B x 3.4x
IFRX ██% $255M x x
IGC ██% $27M x 4.4x
IMMP ██% $57M x x
IMMX ██% $626M x 7.4x
IMNM ██% $2.49B x 4.2x
IMNN ██% $6M x 1.8x
IMRN ██% $9M x x
IMRX ██% $284M x 1.4x
IMUX ██% $195M x 1.3x
INBP ██% $5M x 0.3x
INDP ██% $369M x 295.8x
INDV ██% $5.02B 19.9x x
INM ██% $10M x 1.4x
INO ██% $84M x 13.8x
INSM ██% $23.26B x 33.0x
INTI ██% $15M x x
INVA ██% $1.58B 3.1x 1.2x
IOBTQ ██% $70K x 0.1x
IONS ██% $9.27B x 18.9x
IRD ██% $241M x x
IRON ██% $2.87B x 4.2x
IRWD ██% $624M 6.1x x
ISCO ██% $2M x x
IVA ██% $1.07B x x
IXHL ██% $38M x 0.5x
JAGX ██% $5M x x
JANX ██% $957M x 1.0x
JAZZ ██% $15.78B 534.9x 3.5x
JBIO ██% $1.19B x 4.0x
JNJ ██% $624.17B 29.7x 7.4x
JUNS ██% $6M x x
KALA ██% $11M x 1.1x
KALV ██% $1.38B x x
KAPA ██% $6M x 1.2x
KAYS ██% $140K x x
KMDA ██% $401M x x
KNSA ██% $4.82B 66.0x 8.0x
KPRX ██% $10M x 0.7x
KPTI ██% $160M x x
KROS ██% $200M x 0.7x
KRRO ██% $166M x 1.4x
KTTA ██% $16M x 0.3x
KURA ██% $928M x 8.6x
KYNB ██% $29M 0.2x x
LAB ██% $343M 4.4x 0.6x
LBRX ██% $993M x 2.6x
LEGN ██% $4.55B x x
LEXX ██% $14M x 3.0x
LFCR ██% $166M x x
LFVN ██% $79M 10.0x 2.4x
LGND ██% $6.05B 39.4x 6.1x
LGVN ██% $19M x 1.2x
LIANY ██% $12M x 0.1x
LIFD ██% $3M x 0.4x
LIPO ██% $150K x 0.1x
LITS ██% $35M x 0.6x
LIXT ██% $120M x 15.2x
LKFT ██% $1.85B x x
LLY ██% $1.07T 42.4x 34.4x
LNAI ██% $11M x x
LPCN ██% $16M x 0.7x
LQDA ██% $7.86B 352.5x 72.4x
LRMR ██% $403M x 2.6x
LSTA ██% $19M x 1.8x
LTRN ██% $32M x 9.4x
LXRX ██% $943M x 4.7x
LYEL ██% $298M x 1.1x
MAIA ██% $78M x 2.8x
MANE ██% $4.84B x 12.4x
MBIO ██% $4M x 0.5x
MBRX ██% $16M x 1.0x
MBX ██% $3.02B x 6.9x
MCRB ██% $50M x 1.9x
MDCX ██% $22M x 16.4x
MDGL ██% $12.52B x 23.0x
MGNX ██% $255M x 12.0x
MIRA ██% $39M x 4.2x
MIRM ██% $6.97B x 28.7x
MIST ██% $141M x 3.9x
MLTX ██% $1.62B x 6.4x
MLYS ██% $2.23B x 3.5x
MNKD ██% $1.20B x x
MNOV ██% $64M x 1.6x
MNPR ██% $708M x 5.2x
MPLT ██% $1.59B x 4.0x
MREO ██% $46M x 1.4x
MRK ██% $322.55B 36.1x 7.0x
MRKR ██% $20M x 1.5x
MRVI ██% $2.60B x 12.3x
MSLE ██% $200M x x
MTNB ██% $2M x 0.5x
MTVA ██% $8M x 0.9x
NAMS ██% $3.56B x 5.4x
NATR ██% $360M 18.1x 2.2x
NBP ██% $205M x 0.8x
NBTX ██% $1.91B x x
NCEL ██% $20M x 37.7x
NCNA ██% $6M x x
NERV ██% $195M x x
NEUP ██% $21M x 0.7x
NGNE ██% $710M x 3.0x
NIKA ██% $806M x x
NKTR ██% $2.34B x 4.1x
NKTX ██% $171M x 0.6x
NMAD ██% $89M x 11.2x
NNVC ██% $33M x 3.6x
NRIX ██% $2.46B x 6.1x
NRSN ██% $24M x x
NRXP ██% $176M x x
NSRX ██% $36M x 13.1x
NTHI ██% $90M x x
NUVB ██% $2.25B x 7.0x
NUVL ██% $9.75B x 8.3x
NVCT ██% $635M x 44.7x
NVS ██% $297.94B x x
NWBO ██% $273M x x
NXTC ██% $17M x 0.6x
NXTS ██% $3M x 0.2x
OCUL ██% $1.89B x 3.2x
OGEN ██% $2M x 0.4x
OGI ██% $130M x x
OGN ██% $3.56B 14.5x 3.9x
OKUR ██% $170M x 0.9x
OLMA ██% $1.03B x 2.1x
OMER ██% $740M 8.6x x
ONC ██% $33.90B 66.1x 7.1x
ONCO ██% $3M x 0.3x
ONCY ██% $99M x x
OPK ██% $888M x 0.7x
ORGO ██% $313M 115.0x 1.3x
ORIC ██% $1.13B x 2.7x
ORKA ██% $5.55B x 11.4x
ORMP ██% $170M 1.6x 0.7x
OSTX ██% $61M x x
OTLC ██% $13M x 0.1x
OVID ██% $401M x 2.0x
OWPC ██% $110K x x
PAHC ██% $1.38B 14.5x 3.8x
PBH ██% $2.37B 12.5x 1.3x
PBM ██% $11M x x
PBYI ██% $408M 16.7x 3.2x
PCRX ██% $1.02B 198.4x 1.6x
PCSA ██% $8M x 3.0x
PCYN ██% $2M x 1.0x
PDSB ██% $39M x 10.1x
PEPG ██% $145M x 1.1x
PFE ██% $142.33B 19.0x 1.6x
PGEN ██% $1.97B x 97.4x
PHAT ██% $922M x x
PHIO ██% $12M x 0.8x
PHVS ██% $2.32B x x
PKTX ██% $3M x 10.3x
PLRX ██% $67M x 0.4x
PLYX ██% $100M x 40.2x
PMHS ██% $2M x x
PMN ██% $113M x 1.9x
PMVP ██% $71M x 0.8x
PPBT ██% $1M x x
PPCB ██% $3M x 0.3x
PRAX ██% $8.98B x 6.4x
PRFX ██% $4M x 0.4x
PRGO ██% $1.39B x 0.6x
PRLD ██% $324M x 5.4x
PRPH ██% $840K x 0.1x
PRQR ██% $253M x x
PRTA ██% $453M x 1.5x
PTCT ██% $6.50B x x
PTGX ██% $8.70B x 13.3x
PTIX ██% $420K x x
PTN ██% $14M x 1.4x
PTPI ██% $170K 0.0x 0.1x
PULM ██% $6M x 1.8x
PVCT ██% $26M x x
PVLA ██% $2.05B x 8.8x
PYXS ██% $168M x 5.4x
QNRX ██% $9M x 1.0x
QNTM ██% $21M x x
QTTB ██% $457M 13.7x 9.9x
QUCY ██% $25M x 5.5x
QURE ██% $2.49B x 16.6x
RADX ██% $34M x x
RANI ██% $122M x 4.3x
RAPP ██% $1.98B x 4.2x
RARE ██% $2.66B x x
RCKT ██% $358M x 1.5x
RCUS ██% $3.67B x 7.0x
RDY ██% $9.85B x x
REGN ██% $67.80B 15.3x 2.2x
REVB ██% $4M x 0.3x
RFL ██% $118M x 1.6x
RGBP ██% $80K x x
RIGL ██% $678M 1.9x 1.7x
RKTO ██% $19M x 4.5x
RLMD ██% $546M x 2.5x
RLYB ██% $87M x 1.7x
RMHI ██% $25M x x
RMTI ██% $27M x 0.7x
RNAC ██% $229M x x
RNAZ ██% $7M x 5.5x
RNTX ██% $68M x 5.9x
RNXT ██% $43M x 3.8x
ROIV ██% $25.28B x 5.6x
RPRX ██% $33.99B 41.1x 4.9x
RTEZ ██% $1.93B x x
RVPH ██% $6M x 0.4x
RVRC ██% $101M x 16.5x
RYTM ██% $7.03B x 57.2x
RZLT ██% $466M x 4.0x
SBFM ██% $3M x 0.1x
SCNX ██% $16M x 0.2x
SCYX ██% $290M x 7.0x
SDEV ██% $30M 0.1x 0.2x
SDGR ██% $1.12B x 3.6x
SEPN ██% $1.50B x 4.0x
SER ██% $31M x 1.8x
SGMT ██% $433M x 4.2x
SHPH ██% $2M x 0.5x
SIGA ██% $228M 11.3x 1.5x
SILO ██% $5M x 0.9x
SION ██% $2.14B x 7.4x
SKVI ██% $1M x x
SKYE ██% $24M x 2.6x
SLGL ██% $261M x 11.5x
SLN ██% $541M x 11.0x
SLS ██% $2.24B x 20.8x
SMMT ██% $11.88B x 18.9x
SMNR ██% $157M x x
SNDX ██% $1.90B x 45.6x
SNGX ██% $5M x 1.8x
SNSE ██% $31M x x
SNY ██% $106.10B x x
SPRB ██% $124M x 3.6x
SPRC ██% $3M x x
SPRO ██% $69M 4.5x 1.3x
SPRY ██% $596M x 9.7x
SRPT ██% $1.73B 26.6x 1.2x
STOK ██% $1.89B x 4.8x
STTK ██% $702M x 7.3x
SUPN ██% $2.75B x 2.6x
SVRA ██% $1.16B x 6.6x
SXTP ██% $4M x 0.9x
SYBX ██% $8M x 0.6x
SYRE ██% $7.88B x 11.7x
TAK ██% $55.84B x x
TBPH ██% $870M 7.6x 3.0x
TCRT ██% $5M x 3.5x
TELO ██% $82M x 16.5x
TENX ██% $416M x 3.6x
TEVA ██% $36.16B 23.1x 4.4x
TGTX ██% $8.68B 18.8x 14.9x
TLPH ██% $65M x 3.5x
TLX ██% $3.38B x x
TNGX ██% $4.37B x 11.2x
TNXP ██% $165M x 0.7x
TOVX ██% $10M x 0.7x
TPST ██% $15M x 18.3x
TRDA ██% $236M x 0.9x
TRVI ██% $2.31B x 13.4x
TTRX ██% $243M x 39.7x
TVRD ██% $23M x 1.6x
TVTX ██% $5.27B x 53.4x
TXMD ██% $24M 132.6x 0.9x
TYRA ██% $1.89B x 4.9x
UNCY ██% $131M x 3.5x
UPB ██% $344M x 1.1x
URGN ██% $1.99B x x
UTHR ██% $26.39B 20.5x 4.5x
VBIO ██% $900K x 0.1x
VCNX ██% $3M x x
VERA ██% $2.54B x 5.1x
VGLS ██% $240K x x
VICP ██% $47M x x
VKTX ██% $4.04B x 8.1x
VNDA ██% $319M x 1.1x
VRCA ██% $87M x 5.4x
VRDN ██% $2.05B x 3.2x
VREOD ██% $491M x 1.7x
VREOF ██% $491M x 1.7x
VRTX ██% $122.36B 28.2x 6.3x
VSTM ██% $551M x 6.7x
VTGN ██% $9M x 0.2x
VTRS ██% $20.28B x 1.4x
VYNE ██% $17M x 0.7x
WHWK ██% $174M x 1.5x
WVE ██% $1.15B x 2.2x
XBIO ██% $6M x 0.8x
XBIT ██% $69M x 0.5x
XCUR ██% $11M x 5.2x
XENE ██% $6.28B x 4.7x
XERS ██% $1.45B 120.6x 111.3x
XLO ██% $58M x 0.8x
XNCR ██% $1.48B x 2.9x
XOMA ██% $710M 21.0x 7.7x
XTLB ██% $7M x x
ZBIO ██% $2.07B x 6.2x
ZLAB ██% $2.09B x 3.2x
ZNTL ██% $321M x 1.8x
ZTS ██% $32.38B 12.3x 10.0x
ZVRA ██% $571M 4.6x 2.8x
ZVSA ██% $940K x x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Bridgebio Oncology Therapeutics, Inc. Stock Forecast

How accurate are Bridgebio Oncology Therapeutics, Inc. stock predictions?

Our AI model shows a 47% Spearman correlation coefficient for BBOT predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Bridgebio Oncology Therapeutics, Inc. stock price forecasts?

Our analysis considers Bridgebio Oncology Therapeutics, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Bridgebio Oncology Therapeutics, Inc. a good investment in 2025?

Based on our AI analysis, Bridgebio Oncology Therapeutics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Bridgebio Oncology Therapeutics, Inc. forecasts updated?

Bridgebio Oncology Therapeutics, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Bridgebio Oncology Therapeutics, Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...